Bristol-myers Squibb Compnay

Hong Wu

John T Hynes

John V Duncia

Joseph B Santella

Satheesh Kesavan Nair

Daniel S Gardner

Venkatram Reddy Paidi

Jagabandhu Das

Stephen T Wrobleski

Natesan Murugesan

Sreekantha Ratna Kumar

Ramesh Kumar Sistla

Katerina Leftheris

William John Pitts

Shuqun Lin

Rajeev S Bhide

Steven H Spergel

John S Tokarski

Bin Jiang

Bingwei Vera Yang

Junqing Guo

Kandhasamy Sarkunam

James Kempson

John E Macor

Jingwu Duan

Chunjian Liu

Zhonghui Lu

Robert V Moquin

Lidia M Doweyko

Subba Rao Polimera

Ping Chen

Saleem Ahmad

Percy H Carter

Jayakumar Sankara Warrier

Xiao Zhu

Lyndon A M Cornelius

Ling Li

George V De Lucca

Gregory D Brown

Tg Murali Dhar

Piramanayagam Arunachalam

Durgarao Kantheti

Lyndon AM Cornelius

TG Murali Dhar

Natessan Murugesan

Das Jagabandhu

Joseph B Santella Iii

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein R, R, R, R, and are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as IRAK4 inhibitors

Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or a salt or prodrug thereof, wherein: X is CR4 or N; and R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors

Disclosed are compounds of Formula (I) Formula (I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[1,2-b]pyridazin-3-yl, and pyrazolo[1,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 R; and R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer. 

Heteroaryl substituted aminopyridine compounds

Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Ris a monocyclic heteroaryl group, and R, R, R, Rand Rare as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

Heteroaryl substituted pyridyl compounds useful as kinase modulators

Disclosed are compounds of Formula (I) or salts thereof, wherein HET is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 R; A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 R; and R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer. 

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, or triazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer. 

Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Ris a monocyclic heteroaryl group, and R, R, R, Rand Rare as defined herein, are useful as kinase modulators, including IRAK-4 inhibition. 

Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Ris a bicyclic heterocycle, and R, R, R, Rand Rare as defined herein, that are useful as kinase modulators, including IRAK-4 modulation. 

Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. 

Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Rand R; and Rand Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

Heteroaryl substituted nicotinamide compounds

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. 

Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases. 

The present application describes prodrugs of the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis using the prodrug compounds of the invention are disclosed.

Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity

A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase. 

Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors

Growing community of inventors

New Hope, PA, United States of America

Hong Wu